Syensqo (SYENS) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 results were in line with expectations, with sequential improvements in sales and EBITDA, driven by strong performance in Composite Materials and Consumer & Resources, while Specialty Polymers lagged due to lower volumes and pricing.
Free cash flow was €47 million excluding a €167 million NJDEP payment, with cash conversion at 88%; net debt stood at €1.9 billion, leverage ratio 1.3x.
Investment in North American battery materials was rephased by up to two years, reducing annual CapEx and aligning with softer EV demand.
Major capital moves included a €1.2 billion bond issuance, share buyback program, and acquisitions to strengthen the portfolio.
Ongoing macroeconomic uncertainty, high inflation, and slow recovery in key end markets continued to impact demand and customer investment.
Financial highlights
Q2 2024 net sales were €1.7 billion, down 5.9% year-over-year but up 5% sequentially; underlying EBITDA was €378 million, margin 22.1%.
Gross profit margin was 34.1%, down 90 bps year-over-year; basic EPS was €1.51, down 24.5% year-over-year.
Operating cash flow was €43 million; excluding NJDEP payment, €210 million.
Net debt at €1.9 billion, with gearing at 21% and net debt leverage ratio of 1.3x.
Cash conversion (LTM) was 77%, or 88% excluding the NJDEP payment.
Outlook and guidance
Full-year 2024 underlying EBITDA expected at €1.4–1.475 billion; free cash flow (excluding NJDEP payment) forecast at €400–450 million; CapEx projected at €600–650 million.
Management anticipates a return to year-over-year volume growth in H2 2024, especially in Novecare, but expects a slower recovery in Automotive, Agro, Industrial, and Medical markets.
Q4 could see a 10–20% sequential EBITDA decline depending on seasonal trends and customer cash management.
Net pricing reduction of €50–100 million and dissynergies (~€30 million) expected in 2024.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025